PNEUMOCOCCAL DISEASE
Clinical trials for PNEUMOCOCCAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new PNEUMOCOCCAL DISEASE trials appear
Sign up with your email to follow new studies for PNEUMOCOCCAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 20-Strain pneumonia vaccine moves to safety testing in china
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine (20vPnC) that protects against 20 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. About 200 healthy Chinese adults, children, and infants will receive the vaccine at different ages and schedules. Researchers w…
Matched conditions: PNEUMOCOCCAL DISEASE
Phase: PHASE1 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 08:10 UTC
-
New infant vaccine trial aims to improve protection against pneumococcal disease
⭐️ VACCINE ⭐️ OngoingThis study tests a new pneumococcal vaccine (PG4) in healthy infants to see if it is safe and helps their bodies fight off germs that cause pneumococcal disease. About 605 infants will receive either the new vaccine or a currently used one. Researchers will check for side effects…
Matched conditions: PNEUMOCOCCAL DISEASE
Phase: PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 08:09 UTC
-
New pneumonia vaccine trial aims to boost protection in adults
⭐️ VACCINE ⭐️ OngoingThis study tests a new pneumococcal vaccine in adults 18 and older to see if it is safe and helps the body fight off pneumococcal disease. About 558 participants will receive either the new vaccine or a licensed one. The trial has four stages, with different age groups and vaccin…
Matched conditions: PNEUMOCOCCAL DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 08:08 UTC
-
New pneumonia vaccine under safety watch in japanese infants
⭐️ VACCINE ⭐️ OngoingThis study checks the safety of the PREVENAR 20 vaccine in infants aged 2 to 6 months in Japan. About 1,100 babies will receive four doses as part of their routine shots. Researchers will track any side effects from the first dose until 28 days after the last dose.
Matched conditions: PNEUMOCOCCAL DISEASE
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 20, 2026 11:54 UTC